ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 41 - 60 ( 246 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Lavender Data Provides the Foundation for Encouraging Launch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Launch, Pricing, and DDI Post Daybue Approval; Reit. Buy and Increasing Our PT to $28
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Looking at Trofinetide Ahead of PDUFA; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Learnings From the ADVANCE-1 Guides the Negative Symptom Program; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Trofinetide?s Safety and Efficacy Data; Reit. Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Trofinetide Might Become the Second CNS Specific Drug for Acadia; Reit. Buy and PT Up to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Thoughts On What is Next After ADP for Acadia; PT Down to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Thoughts On What is Next After ADP for Acadia; PT Down to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Acadia''s Opportunity to Convince the Panel On Additional Analyses-Thoughts On the Briefing Document
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A